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Mitochondria are the bioenergetic cen-
ters of eukaryotic cells that produce ATP
through oxidative phosphorylation. A by-
product of oxidative phosphorylation is
the generation of reactive oxygen species
(ROS). Cancer cells exhibit high basal
levels of oxidative stress due to activation
of oncogenes, loss of tumor suppressors,
and the effects of the tumor microenvi-
ronment [1]. A large body of evidence
suggests important roles for oxygen free
radicals in the mutagenesis that drives
carcinogenesis [2], the expansion of tumor
clones, and the acquisition of malignant
properties [3].
Several studies have reported that a
high frequency of clonal and, therefore,
selected mitochondrial mutations are pres-
ent in a variety of human tumors [4–15].
Mitochondrial DNA (mtDNA) mutations
in cancer cells include intragenic deletions,
missense and chain-termination point
mutations, and alterations of homopoly-
meric sequences that result in frameshift
mutations [16,17]. The biological impact
of a given mutation may vary, depending
on the proportion of mutant mtDNAs
carried by the cell. The assumption from
these studies is that this high frequency of
clonal mutations arises from the ROS
produced in mitochondria by the escape of
oxygen free radicals during oxidative
phosphorylation, and that these mutations
play a role in driving cancer (Figure 1).
Therefore, genomic instability of mito-
chondria was thought to be a hallmark of
cancer.
Cancer arises from a mutator pheno-
type and it has been established that the
random mutation rate of the nuclear DNA
of tumors is quite high [18]. However,
little is known about the random mutation
rates of mitochondria derived from tu-
mors. In this issue of PLoS Genetics, Ericson
and colleagues [19] report their striking
finding that the random mutation fre-
quency of colorectal tumor mtDNA is
significantly lower than that of nuclear
DNA or of mtDNA in the surrounding
normal tissue. These results were obtained
using the random mutation capture assay
that was developed to measure random,
and not clonal, mutations [19]. This group
also shows that the mitochondria from the
colon tumors use aerobic glycolysis rather
than oxidative phosphorylation to gener-
ate energy for the cells. Importantly, this
metabolic shift from oxidative phosphory-
lation to aerobic glycolysis is likely to
produce fewer ROS that damage mtDNA
and lead to mutagenesis, mitochondrial
dysfunction, and cell death.
Seven decades ago, Warburg discovered
that mitochondria in cancer cells metab-
olize glucose by aerobic glycolysis and
suggested that this was a result of impaired
mitochondrial function that contributes to
tumorigenesis [20,21]. Recently, Thomp-
son and colleagues suggested that mito-
chondrial function itself is not impaired in
cancer cells that metabolize glucose by
aerobic glycolysis, and that this type of
anabolic metabolism is critical for the
production of essential cellular building
blocks including dNTPs, amino acids, and
lipids [22] (Figure 1). Growth factor
signaling by activated AKT, Myc, and
other proto-oncogenes results in altered
mitochondrial metabolism [22]. For ex-
ample, a majority of human tumors
harbor mutations in the AKT gene, and
activated AKT enhances glucose uptake,
allowing cells to maintain a higher than
adequate level of ATP [23]. What is
unknown is whether the colon tumors that
were characterized by the Bielas group
[19] harbor activated proto-oncogenes.
Nevertheless, the picture that now emerg-
es is that aerobic glycolysis enhances
growth of cancer cells by anabolic metab-
olism without producing high levels of
ROS that could inactivate the power
supply of the cell.
Other explanations for the low frequen-
cy of random mitochondrial mutations in
colon tumors include highly efficient DNA
repair (for excellent review see [24]) and
the coupling of antioxidant proteins to the
NADPH/NADP balance (Figure 1). Re-
cent studies have demonstrated that
mtDNA is repaired by a variety of
mechanisms, including short- and long-
patch base excision repair, mismatch
repair, and homologous recombination
[24–27]. The sanitation of dNTPs is also
likely to result in fewer mutations. Anti-
oxidant proteins may also play a role in
the low random mutation rate observed in
mitochondria. Proteins such as reduced
glutathione (GSH) or thioredoxin that are
closely coupled to the NADPH/NADP
balance can inactivate ROS [28,29]. The
presence of NADPH and other free radical
scavengers may be more pronounced in
the colorectal tumor environment to
neutralize the impact of oxidative stress
(Figure 1).
What are the implications of the
findings of Ericson et al. [19] for future
cancer therapy strategy or biomarker
discovery? Cancer cells exhibit increased
uptake of glucose, which increases the
bioenergetic competence required of ma-
lignant cells. This metabolic feature has
led to the hypothesis that inhibition of
glycolysis may abolish ATP and important
precursor generation in cancer cells and
thus may preferentially kill the malignant
cells [30,31]. Nuclear genetic and epige-
netic changes have been the cornerstone of
such studies. In addition to these strate-
gies, it is likely that mutated genes that
function to alter mitochondrial metabolic
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and MYC, will emerge as new drug targets
and molecular markers of prognosis and
responses to therapy. In addition, target-
ing mtDNA repair proteins could serve as
a potential alternative approach to kill
cancer cells. The work of the Ericson et al.
[19] adds significantly to our understand-
ing of the roles of mitochondria in
supporting the growth of tumors. In
combination with recent findings regard-
ing mitochondrial metabolism in cancer
cells, this groundbreaking finding suggests
that novel drugs that target the power-
house of cancer cells are likely to make a
significant impact on cancer treatment.
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